Stoke Therapeutics CEO Transition Highlights Leadership Changes Stoke Therapeutics has announced that CEO Edward M. Kaye will step down today, March 19, 2025, after seven years of leadership. Ian F. Smith, former Vertex COO, will serve as interim CEO. The company is advancing its lead drug, zorevunersen, into Phase 3 trials for Dravet syndrome.12